Recent Press ReleasesApply12.02.2020Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-1911.23.2020Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors11.20.2020Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine11.19.2020Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine11.18.2020Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints11.16.2020Pfizer Update On Our U.S. COVID-19 Vaccine Candidate Distribution Preparedness11.16.2020Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan11.12.2020Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg11.11.2020Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference11.11.2020Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing RegimensMedia ContactsGet to Know UsCompany Fact SheetFeatured StoriesPodcastsPress Kits @Pfizer @Pfizer_Newsby pfizerTweets by pfizer_news
